APOE and dementia: Dementia progression rates 44.4% (8/18) in estradiol group vs. 52.9% (9/17) in placebo group. Estradiol treatment reduced global cognition deterioration in MCI when adjusted for apoE genotype (ε4 allele) (P = 0.0261) and resulted in better cognitive battery scores after 24 mo vs. placebo on both Korean versions of MCA (MD: 3.85; 95% CI: –0.46, 8.16; P = 0.043) and MMSE (MD: 3.26; 95% CI: 0.04, 6.48; P = 0.0319)